Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | CD4 | P01730 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8203532 | 0.85 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL3971438 | 0.85 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8200466 | 0.85 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL4537086 | 0.85 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL10724066 | 0.85 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL699639 | 0.85 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL565301 | 0.85 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL3303527 | 0.85 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL505093 | 0.84 | KMT2A (0.69) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8218091 | 0.82 | PKM (0.54) | PKMALDH1A1CD4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9074028-B2 | Complexes of ruthenum, method for their preparation, and their application in olefin metathesis reactions | UMICORE AG & CO. KG (DE) | 2015-07-07 | — | — | US | disclosed |
| US-20140171607-A1 | New Complexes of Ruthenium, Method for Their Preparation, and Their Application in Olefin Metathesis Reactions | UMICORE AG & CO. KG (DE) | 2014-06-19 | — | — | US | disclosed |
| US-7645774-B2 | Cannabinoid receptor ligands | SCHERING CORPORATION (US) | 2010-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171607-A1 | New Complexes of Ruthenium, Method for Their Preparation, and Their Application in Olefin Metathesis Reactions | CYP2F1, FIS1, CYP4F11 | PKM 3886/4885HTT 4412/4885ALDH1A1 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.